< 生产厂家价格 >

赛拉嗪

赛拉嗪用途

Xylazine是α2肾上腺素受体激动剂。

点击显示

赛拉嗪名称

[ CAS 号 ]:
7361-61-7

[ 中文名 ]:
甲苄噻嗪

[ 英文名 ]:
Xylazine

[中文别名 ]:

[英文别名 ]:

Rompun
Xylazinum
xylazine
MFCD00057908
Xilazina [INN-Spanish]
EINECS 230-902-1
UNII-2KFG9TP5V8
Xylazinum [INN-Latin]
Xylazin
Xilazina

赛拉嗪生物活性

[ 描述 ]:

Xylazine是α2肾上腺素受体激动剂。

[ 相关类别 ]:

信号通路 >> G 蛋白偶联受体/G 蛋白 >> 肾上腺素能受体

研究领域 >> 神经疾病

[参考文献]

[1]. Reyes, J.C., et al., The emerging of xylazine as a new drug of abuse and its health consequences among drug users in Puerto Rico. J Urban Health, 2012. 89(3): p. 519-26.

[2]. Hsu, W.H., Xylazine-induced depression and its antagonism by alpha adrenergic blocking agents. J Pharmacol Exp Ther, 1981. 218(1): p. 188-92.

[相关活性小分子]

赛拉嗪物理化学性质

[ 密度 ]:
1.2±0.1 g/cm3

[ 沸点 ]:
334.2±52.0 °C at 760 mmHg

[ 熔点 ]:
140ºC

[ 分子式 ]:
C₁₂H₁₆N₂S

[ 分子量 ]:
220.334

[ 闪点 ]:
155.9±30.7 °C

[ 精确质量 ]:
220.103424

[ PSA ]:
49.69000

[ LogP ]:
2.37

[ 蒸汽压 ]:
0.0±0.7 mmHg at 25°C

[ 折射率 ]:
1.611

[ 储存条件 ]:
−20°C

赛拉嗪MSDS

赛拉嗪毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: XJ0776300

CHEMICAL NAME :: 4H-1,3-Thiazine, 5,6-dihydro-2-(2,6-xylidino)-

CAS REGISTRY NUMBER :: 7361-61-7

LAST UPDATED :: 199606

DATA ITEMS CITED :: 8

MOLECULAR FORMULA :: C12-H16-N2-S

MOLECULAR WEIGHT :: 220.36

WISWESSER LINE NOTATION :: T6N CS AUTJ BMR B1 F1

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 8 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Behavioral - changes in motor activity (specific assay) Cardiac - pulse rate

REFERENCE :: CTOXAO Clinical Toxicology. (New York, NY) V.1-18, 1968-81. For publisher information, see JTCTDW. Volume(issue)/page/year: 18,663,1981

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 734 ug/kg

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - miosis (pupillary constriction) Cardiac - pulse rate Vascular - BP lowering not characterized in autonomic section

REFERENCE :: AJEMEN American Journal of Emergency Medicine. (WB Saunders, Philadelphia, PA) V.1- 1983- Volume(issue)/page/year: 4,222,1986

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 22 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Cardiac - pulse rate Lungs, Thorax, or Respiration - pleural thickening

REFERENCE :: AJEMEN American Journal of Emergency Medicine. (WB Saunders, Philadelphia, PA) V.1- 1983- Volume(issue)/page/year: 4,222,1986

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 130 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: DTTIAF Deutsche Tieraerztliche Wochenschrift. (Hanover, Fed. Rep. Ger.) V.1-77, 1893-1970. Volume(issue)/page/year: 75,565,1968

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 240 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: DTTIAF Deutsche Tieraerztliche Wochenschrift. (Hanover, Fed. Rep. Ger.) V.1-77, 1893-1970. Volume(issue)/page/year: 75,565,1968

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 121 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: DTTIAF Deutsche Tieraerztliche Wochenschrift. (Hanover, Fed. Rep. Ger.) V.1-77, 1893-1970. Volume(issue)/page/year: 75,565,1968

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 18 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: CSLNX* U.S. Army Armament Research & Development Command, Chemical Systems Laboratory, NIOSH Exchange Chemicals. (Aberdeen Proving Ground, MD 21010) Volume(issue)/page/year: NX#10054 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - E0475 No. of Facilities: 403 (estimated) No. of Industries: 1 No. of Occupations: 5 No. of Employees: 4029 (estimated) No. of Female Employees: 2015 (estimated)

点击显示

赛拉嗪安全信息

[ 符号 ]:

GHS06

[ 信号词 ]:
Danger

[ 危害声明 ]:
H301

[ 警示性声明 ]:
Missing Phrase - N15.00950417

[ 个人防护装备 ]:
Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges

[ 危害码 (欧洲) ]:
T:Toxic;

[ 风险声明 (欧洲) ]:
R25

[ 安全声明 (欧洲) ]:
S45

[ 危险品运输编码 ]:
UN 2811

[ WGK德国 ]:
3

[ RTECS号 ]:
XJ0776300

[ 包装等级 ]:
III

[ 危险类别 ]:
6.1

[ 海关编码 ]:
2934999090

赛拉嗪合成路线

赛拉嗪上下游产品

赛拉嗪上游产品

赛拉嗪下游产品

赛拉嗪海关

[ 海关编码 ]: 2934999090

[ 中文概述 ]:
2934999090. 其他杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%

[ 申报要素 ]: 品名, 成分含量, 用途

[ Summary ]:
2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

赛拉嗪文献

Protective effects of glucosamine on oxidative-stress and ischemia/reperfusion-induced retinal injury.

Invest. Ophthalmol. Vis. Sci. 56(3) , 1506-16, (2015)

To investigate the protective effects of glucosamine (GlcN) using oxidative stress and rat models of ischemia-reperfusion (I/R) injury and to determine the antiapoptotic and anti-inflammatory mechanis...

Adipose-derived stromal vascular fraction cells isolated from old animals exhibit reduced capacity to support the formation of microvascular networks.

Exp. Gerontol. 63 , 18-26, (2015)

Adipose-derived regenerative and stem cells, defined collectively as the stromal vascular fraction (SVF), support the formation of neovascular networks at the site of implantation. The effect of advan...

Enhanced Retinal Ganglion Cell Survival in Glaucoma by Hypoxic Postconditioning After Disease Onset.

Neurotherapeutics 12(2) , 502-14, (2015)

The neuroprotective efficacy of adaptive epigenetics, wherein beneficial gene expression changes are induced by nonharmful "conditioning" stimuli, is now well established in several acute, preclinical...

更多文献

赛拉嗪